share_log

Berenberg Initiates Coverage On Blueprint Medicines With Buy Rating, Announces Price Target of $90

Benzinga Real-time News ·  Sep 14, 2022 06:46

Berenberg analyst Zhiqiang Shu initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Buy rating and announces Price Target of $90.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment